Recombinant Modified Vaccinia Virus Ankara–Based Vaccine Induces Protective Immunity in Mice against Infection with Influenza Virus H5N1 | Zendy

Joost H. C. M. Kreijtz | Zendy; Yasemin Suezer | Zendy; Geert van Amerongen | Zendy; Gerrie de Mutsert | Zendy; Barbara S. Schnierle | Zendy; John Wood | Zendy; Thijs Kuiken | Zendy; Ron A. M. Fouchier | Zendy; Johannes Löwer | Zendy; Albert D. M. E. Osterhaus | Zendy; Gerd Sutter | Zendy; Guus F. Rimmelzwaan | Zendy

Open Access

Recombinant Modified Vaccinia Virus Ankara–Based Vaccine Induces Protective Immunity in Mice against Infection with Influenza Virus H5N1

Author(s) -

Joost H. C. M. Kreijtz,

Yasemin Suezer,

Geert van Amerongen,

Gerrie de Mutsert,

Barbara S. Schnierle,

John Wood,

Thijs Kuiken,

Ron A. M. Fouchier,

Johannes Löwer,

Albert D. M. E. Osterhaus,

Gerd Sutter,

Guus F. Rimmelzwaan

Publication year - 2007

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/517614

Subject(s) - virology , influenza a virus subtype h5n1 , hemagglutinin (influenza) , virus , biology , immunity , vaccination , vaccinia , modified vaccinia ankara , influenza a virus , recombinant dna , microbiology and biotechnology , immunology , immune system , gene , biochemistry

Since 2003, the number of human cases of infections with highly pathogenic avian influenza viruses of the H5N1 subtype is still increasing, and, therefore, the development of safe and effective vaccines is considered a priority. However, the global production capacity of conventional vaccines is limited and insufficient for a worldwide vaccination campaign. In the present study, an alternative H5N1 vaccine candidate based on the replication-deficient modified vaccinia virus Ankara (MVA) was evaluated. C57BL/6J mice were immunized twice with MVA expressing the hemagglutinin (HA) gene from influenza virus A/Hongkong/156/97 (MVA-HA-HK/97) or A/Vietnam/1194/04 (MVA-HA-VN/04). Subsequently, recombinant MVA-induced protective immunity was assessed after challenge infection with 3 antigenically distinct strains of H5N1 influenza viruses: A/Hongkong/156/97, A/Vietnam/1194/04, and A/Indonesia/5/05. Our data suggest that recombinant MVA expressing the HA of influenza virus A/Vietnam/1194/04 is a promising alternative vaccine candidate that could be used for the induction of protective immunity against various H5N1 influenza strains.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research